Adrenocortical carcinoma other imaging studies: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Adrenocortical carcinoma}}
{{Adrenocortical carcinoma}}
{{CMG}} {{AE}} {{AAM}}
{{CMG}}; {{AE}} {{AAM}} {{MAD}}
==Overview==
==Overview==
Adrenal [[angiography]],[[venography]], positron emission tomography and MIBG may be used in the diagnosis of adrenocortical carcinoma.
[[Adrenal]] [[angiography]], [[venography]], [[positron emission tomography]] and [[Metaiodobenzylguanidine|MIBG scan]] may be used in the diagnosis of adrenocortical carcinoma. The [[Sensitivity (tests)|sensitivity]] of [[FDG]] [[PET scan|PET/CT]] was 90% for the diagnosis of [[metastases]] as compared with 88% for the diagnostic [[Computed tomography|CT]]. [[FDG]] [[PET scan|PET/CT]] is a useful modality for [[Cancer staging|staging]] ACC and evaluating local recurrence.
==Other Imaging Studies==
==Other Imaging Studies==
Other Imaging studies that may be used in diagnosis of adrenocortical carcinoma are:<ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/adrenocortical/patient/adrenocortical-treatment-pdq#section/_1</ref>
Other [[imaging]] studies that may be used in the [[diagnosis]] of adrenocortical carcinoma are: <ref name="cancergov">National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/adrenocortical/patient/adrenocortical-treatment-pdq#section/_1</ref>
*Adrenal [[angiography]]
*[[Adrenal]] [[angiography]]
*Adrenal [[venography]]  
*[[Adrenal]] [[venography]]  
*[[PET scan]] (positron emission tomography scan)
*[[PET scan]] ([[positron emission tomography]] scan)
*MIBG scan
*[[Metaiodobenzylguanidine|MIBG scan]]
*[[Bone scan]]s are used to visualize bone [[metastasis]]
*[[Bone scan]]s are used to visualize [[bone]] [[metastasis]]


==== FDG PET/CT ====
==== FDG PET/CT ====
* ACC presents as a large, heterogeneous mass with intense [[FDG]] uptake.<ref name="pmid22737189" />
* ACC presents as a large, [[heterogeneous]] mass with intense [[FDG]] uptake.<ref name="pmid22737189" />
* [[FDG]] [[PET scan|PET/CT]] had a [[Sensitivity (tests)|sensitivity]] of 100% and [[Specificity (tests)|specificity]] of 88% in distinguishing [[benign]] from [[malignant]] lesions by using cutoff value above 1.45 for [[Adrenal gland|adrenal]] to [[liver]] maximum standardized uptake value (SUV).  
* [[FDG]] [[PET scan|PET/CT]] had a [[Sensitivity (tests)|sensitivity]] of 100% and [[Specificity (tests)|specificity]] of 88% in distinguishing [[benign]] from [[malignant]] lesions by using cut-off value above 1.45 for [[Adrenal gland|adrenal]] to [[liver]] maximum standardized uptake value (SUV).  
* [[PET scan|PET/CT]] cannot distinguish ACC from [[Metastasis|metastases]], [[lymphoma]], or [[pheochromocytoma]] due to the high metabolic activity of these tumors.<ref name="pmid22737189">{{cite journal| author=Sundin A| title=Imaging of adrenal masses with emphasis on adrenocortical tumors. | journal=Theranostics | year= 2012 | volume= 2 | issue= 5 | pages= 516-22 | pmid=22737189 | doi=10.7150/thno.3613 | pmc=3364557 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22737189  }}</ref>
* [[PET scan|PET/CT]] cannot distinguish ACC from [[Metastasis|metastases]], [[lymphoma]], or [[pheochromocytoma]] due to the high metabolic activity of these [[tumors]].<ref name="pmid22737189">{{cite journal| author=Sundin A| title=Imaging of adrenal masses with emphasis on adrenocortical tumors. | journal=Theranostics | year= 2012 | volume= 2 | issue= 5 | pages= 516-22 | pmid=22737189 | doi=10.7150/thno.3613 | pmc=3364557 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22737189  }}</ref>
* [[FDG]] [[PET scan|PET/CT]] is a useful modality for staging ACC and evaluating local recurrence.  
* [[FDG]] [[PET scan|PET/CT]] is a useful modality for staging ACC and evaluating local recurrence.  
* Increased uptake of [[FDG]] may be seen in benign conditions including postoperative changes.
* Increased uptake of [[FDG]] may be seen in [[benign]] conditions including postoperative changes.
* No significant difference in [[Accuracy and precision|accuracy]] was found between visual analysis, SUV analysis, and standardized uptake ratio (defined as the ratio of adrenal SUV activity to liver SUV activity) analysis.<ref name="pmid18397978">{{cite journal| author=Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H et al.| title=[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. | journal=J Clin Endocrinol Metab | year= 2008 | volume= 93 | issue= 6 | pages= 2358-65 | pmid=18397978 | doi=10.1210/jc.2008-0050 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18397978  }}</ref>
* No significant difference in [[Accuracy and precision|accuracy]] was found between visual analysis, SUV analysis, and standardized uptake ratio (defined as the ratio of [[adrenal]] SUV activity to [[liver]] SUV activity) analysis.<ref name="pmid18397978">{{cite journal| author=Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H et al.| title=[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. | journal=J Clin Endocrinol Metab | year= 2008 | volume= 93 | issue= 6 | pages= 2358-65 | pmid=18397978 | doi=10.1210/jc.2008-0050 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18397978  }}</ref>
* The sensitivity of [[FDG]] [[PET scan|PET/CT]] was 90% for the diagnosis of [[metastases]] as compared with 88% for diagnostic [[Computed tomography|CT]].  
* The sensitivity of [[FDG]] [[PET scan|PET/CT]] was 90% for the diagnosis of [[metastases]] as compared with 88% for the diagnostic [[Computed tomography|CT]].  
* [[FDG]] [[PET scan|PET/CT]] has low [[sensitivity]] for characterization of smaller lesions, particularly for those lesions less than 10 mm in diameter.<ref name="pmid16621901">{{cite journal| author=Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ et al.| title=Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. | journal=J Clin Endocrinol Metab | year= 2006 | volume= 91 | issue= 7 | pages= 2665-71 | pmid=16621901 | doi=10.1210/jc.2005-2612 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16621901  }}</ref>
* [[FDG]] [[PET scan|PET/CT]] has low [[sensitivity]] for characterization of smaller lesions, particularly for those lesions less than 10 mm in diameter.<ref name="pmid16621901">{{cite journal| author=Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ et al.| title=Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. | journal=J Clin Endocrinol Metab | year= 2006 | volume= 91 | issue= 7 | pages= 2665-71 | pmid=16621901 | doi=10.1210/jc.2005-2612 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16621901  }}</ref>
* Intensity of [[FDG]] uptake was found to be related to survival in patients with ACC, with a maximum SUV of >10 indicating a poor prognosis.<ref name="pmid16621901" />
* The intensity of [[FDG]] uptake was found to be related to survival in patients with ACC, with a maximum SUV of >10 indicating a poor [[prognosis]].<ref name="pmid16621901" />


==References==
==References==

Latest revision as of 19:22, 30 October 2017

Adrenocortical carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Adrenocortical carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

MRI

CT

Ultrasound

Other Imaging Studies

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Radiation Therapy

Primary prevention

Secondary prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Study

Case #1

Adrenocortical carcinoma other imaging studies On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Adrenocortical carcinoma other imaging studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adrenocortical carcinoma other imaging studies

CDC on Adrenocortical carcinoma other imaging studies

Adrenocortical carcinoma other imaging studies in the news

Blogs on Adrenocortical carcinoma other imaging studies

Hospitals Treating Adrenocortical carcinoma

Risk calculators and risk factors for Adrenocortical carcinoma other imaging studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2] Mohammed Abdelwahed M.D[3]

Overview

Adrenal angiography, venography, positron emission tomography and MIBG scan may be used in the diagnosis of adrenocortical carcinoma. The sensitivity of FDG PET/CT was 90% for the diagnosis of metastases as compared with 88% for the diagnostic CT. FDG PET/CT is a useful modality for staging ACC and evaluating local recurrence.

Other Imaging Studies

Other imaging studies that may be used in the diagnosis of adrenocortical carcinoma are: [1]

FDG PET/CT

  • ACC presents as a large, heterogeneous mass with intense FDG uptake.[2]
  • FDG PET/CT had a sensitivity of 100% and specificity of 88% in distinguishing benign from malignant lesions by using cut-off value above 1.45 for adrenal to liver maximum standardized uptake value (SUV).
  • PET/CT cannot distinguish ACC from metastases, lymphoma, or pheochromocytoma due to the high metabolic activity of these tumors.[2]
  • FDG PET/CT is a useful modality for staging ACC and evaluating local recurrence.
  • Increased uptake of FDG may be seen in benign conditions including postoperative changes.
  • No significant difference in accuracy was found between visual analysis, SUV analysis, and standardized uptake ratio (defined as the ratio of adrenal SUV activity to liver SUV activity) analysis.[3]
  • The sensitivity of FDG PET/CT was 90% for the diagnosis of metastases as compared with 88% for the diagnostic CT.
  • FDG PET/CT has low sensitivity for characterization of smaller lesions, particularly for those lesions less than 10 mm in diameter.[4]
  • The intensity of FDG uptake was found to be related to survival in patients with ACC, with a maximum SUV of >10 indicating a poor prognosis.[4]

References

  1. National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/adrenocortical/patient/adrenocortical-treatment-pdq#section/_1
  2. 2.0 2.1 Sundin A (2012). "Imaging of adrenal masses with emphasis on adrenocortical tumors". Theranostics. 2 (5): 516–22. doi:10.7150/thno.3613. PMC 3364557. PMID 22737189.
  3. Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H; et al. (2008). "[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes". J Clin Endocrinol Metab. 93 (6): 2358–65. doi:10.1210/jc.2008-0050. PMID 18397978.
  4. 4.0 4.1 Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ; et al. (2006). "Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma". J Clin Endocrinol Metab. 91 (7): 2665–71. doi:10.1210/jc.2005-2612. PMID 16621901.

Template:WH Template:WS